Reagents and instruments for immunology, cell biology and molecular biology.
 
> Hemin [16009-13-5]

Hemin [16009-13-5]

Print Print
Please log in

Cat# HY-19424-1g

Size : 1g

Brand : MedChemExpress


Hemin is an iron-containing porphyrin. Hemin is an Heme oxygenase (HO)-1 inducer.

For research use only. We do not sell to patients.

Hemin Chemical Structure

Hemin Chemical Structure

CAS No. : 16009-13-5

This product is a controlled substance and not for sale in your territory.

Based on 32 publication(s) in Google Scholar

    Hemin purchased from MedChemExpress. Usage Cited in: Genome Biol. 2022 Dec 15;23(1):259.  [Abstract]

    Hemin (0, 20, 40, 80 µM; 2 h) increases G4 levels in a dose-dependent manner in HeLa cells. Immunostaining of G4 using BG4-EGFP (green). The nuclei are stained with DAPI (blue).
    Description

    Hemin is an iron-containing porphyrin. Hemin is an Heme oxygenase (HO)-1 inducer.

    IC50 & Target

    Heme oxygenase[1]
    In Vitro

    Hemin and PGJ2, used as positive controls, strongly increase both expression and activity of HMOX after 4 and 12 h, respectively. Indeed, a significant effect is found of 30 μM Hemin on cell proliferation in all used cell lines after 48 h, which is dose-dependent. Hemin treatment decreases cell proliferation to 62±5 %, 51±3 %, and 38±8 % in PA-TU-8902, BxPC-3 and MiaPaCa-2 cancer cells, respectively, with p<0.0001 for all comparisons. Furthermore, enhancement of anti-proliferative effects of statins is observed by Hemin, documented as decreased cell proliferation after 48 h of co-treatment[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Hemin Related Antibodies
    In Vivo

    Following the i.p. administration of Hemin (100 μmol/kg), the HO-1 level in the renal cortex begins to increase gradually. The HO-1 level reaches its peak 24 h after Hemin preconditioning. HO-1 is expressed mainly in the renal tubules. The HO-2 level in the kidney does not change following Hemin preconditioning[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    651.94

    Formula

    C34H32ClFeN4O4
    CAS No.

    16009-13-5
    Appearance

    Solid

    Color

    Dark purple to black

    SMILES

    [Cl-][Fe+3]123[N-]4C5=C(CCC(O)=O)C(C)=C4C=C(C(C=C)=C6C)51=C6C=C(C(C=C)=C7C)[N-]2C7=CC(C(C)=C8CCC(O)=O)=53C8=C5
    Structure Classification
    • Others
    Initial Source
    • Animals

    Red blood cells
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    1M NaOH : 6.67 mg/mL (10.23 mM; ultrasonic and adjust pH to 12 with NaOH)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.5339 mL 7.6694 mL 15.3388 mL
    5 mM 0.3068 mL 1.5339 mL 3.0678 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation

    Purity: 99.53%

    COA (258 KB) LCMS (94 KB)

    Handling Instructions (2659 KB)
    References

    • [1]. Vanova K, et al. Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells. BMC Cancer. 2016 May 12;16:309.  [Content Brief]

      [2]. Chen HH, et al. Heme oxygenase-1 ameliorates kidney ischemia-reperfusion injury in mice through extracellular signal-regulated kinase 1/2-enhanced tubular epithelium proliferation. Biochim Biophys Acta. 2015 Oct;1852(10 Pt A):2195-201.  [Content Brief]

    Cell Assay
    [1]

    For the cell proliferation assay, cells are seeded into 96 well (5-12.5×104 cells per mL according to the cell line) and kept at 37°C and 5 % CO2. After 24 h, cells are treated with statins or/and Hemin, followed by the MTT test as a general cell proliferation assay[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [2]

    Mice[2]
    Eight- to ten-week-old male BABL/c mice are used for the ischemia-reperfusion (I/R) experiments. The animals are divided into five groups as follows: (1) the sham group undergo isolation of the bilateral renal arteries without clamping; (2) the vehicle group receive an intraperitoneal (i.p.) injection of 4 mL/kg PBS as a vehicle control (with IRI); (3) the Hemin-preconditioned group receive Hemin, a potent inducer of HO-1, at 100 μmol/kg i.p.; (4) the Hemin plus ZnPP group receive zinc protoporphyrin IX, an inhibitor of HO-1 activity, at 5 mg/kg i.p. 6 h after receiving 100 μmol/kg Hemin i.p.; and (5) the Hemin plus PD98059 group receive PD98059, an inhibitor of ERK1/2 activity, at 10 mg/kg i.p. 6 h after receiving 100 μmol/kg Hemin i.p. Both inhibitors are administered i.p. 2 h before I/R, whereas Hemin was administered 8 h before I/R.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    • [1]. Vanova K, et al. Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells. BMC Cancer. 2016 May 12;16:309.  [Content Brief]

      [2]. Chen HH, et al. Heme oxygenase-1 ameliorates kidney ischemia-reperfusion injury in mice through extracellular signal-regulated kinase 1/2-enhanced tubular epithelium proliferation. Biochim Biophys Acta. 2015 Oct;1852(10 Pt A):2195-201.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    1M NaOH 1 mM 1.5339 mL 7.6694 mL 15.3388 mL 38.3471 mL
    5 mM 0.3068 mL 1.5339 mL 3.0678 mL 7.6694 mL
    10 mM 0.1534 mL 0.7669 mL 1.5339 mL 3.8347 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Hemin Related Classifications

    Help & FAQs

    Keywords:

    Hemin16009-13-5AutophagyMitophagyFerroptosisMitochondrial AutophagyInhibitorinhibitorinhibit

    You might also be interested by the following products:



    Cat#
    Description
    Cond.
    Price Bef. VAT
    TRC-C685401-1MG
    Coproporphyrin I-15N4
     1mg 
    HY-19424-5g
    Hemin [16009-13-5]
     5g